Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
...Diagnosis...
...1. Risk Factors for Multidrug-Resista...
...Micro...
...IDSA suggest noninvasive sampling with semiq...
...ive sampling with semiquantitative c...
...SA suggest that patients with suspected...
...Biomar...
...r patients with suspected HAP/VAP, ATS and IDSA r...
...h suspected HAP/VAP, ATS and IDSA recommend...
...patients with suspected HAP/VAP, ATS and I...
...or patients with suspected HAP/VAP, ATS and IDSA...
Treatment
...Treatment...
...th ventilator-associated tracheobronc...
...A recommend that all hospitals regu...
...and IDSA recommend that empiric treat...
...h suspected VAP, ATS and IDSA recommend includ...
...gest including an agent active agains...
ATS and IDSA suggest including an agent a...
...erage for MRSA is indicated, ATS and IDS...
...piric treatment that includes coverage for MSS...
ATS and IDSA suggest prescribing two anti...
...DSA suggest prescribing one antibiotic...
...with suspected VAP, ATS and IDSA su...
...ients with suspected VAP, ATS and IDSA sugg...
...ecommend that empiric antibiotic regim...
...ecommend that all hospitals regularly ge...
...being treated empirically for HAP, ATS...
...with HAP who are being treated emp...
...r patients with HAP who require empiric cover...
...with HAP who are being treated empiric...
...patients with HAP who are being treated empiri...
...s with HAP who are being treated empirically and...
...ts with HAP who are being treated empirica...
...Optimization...
...ts with HAP/VAP, ATS and IDSA suggest that...
...Inhaled Antibioti...
For patients with VAP due to Gram-n...
...Pathogen-Specific The...
...and IDSA recommend that MRSAHAP/VAP be trea...
...patients with HAP/VAP due to P. aer...
...s with HAP/VAP due to P. aeruginosa, ATS and...
...tients with HAP/VAP due to P. aeruginosa who are...
...h HAP/VAP due to P. aeruginosa who rem...
...r patients with HAP/VAP due to P....
...with HAP/VAP due to extended-spectrum β-l...
...th HAP/VAP caused by Acinetobacter species, ATS...
...ents with HAP/VAP caused by Acinetobact...
...TS and IDSA suggest adjunctive inhaled colistin....
...ents with HAP/VAP caused by Acinetobacter spe...
In patients with HAP/VAP caused by Aci...
...n patients with HAP/VAP caused by a carbapenem-re...
...IDSA suggest adjunctive inhaled colistin. (...
...tients with VAP, ATS and IDSA recommend a...
...th HAP, ATS and IDSA recommend a 7-day course of...
...ents with HAP/VAP, ATS and IDSA sug...
...ith HAP/VAP, ATS and IDSA suggest us...
...with suspected HAP/VAP, ATS and IDSA sugg...
Table 2. Recommended Initial Empiric An...
...Treatment Options for Suspected MRSA/Pseud...